Status:
RECRUITING
Evaluating Disparities in Precision Oncology
Lead Sponsor:
Indiana University
Conditions:
Metastatic Cancer
Advanced Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehen...
Detailed Description
This study proposes an innovative approach leveraging the molecular tumor boards across four comprehensive cancer centers, where real- world, diverse patients with metastatic cancer are seen receiving...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent and HIPAA authorization
- Patients must be ≥ 18 years old at the time of consent
- Patients planning to undergo molecular testing as part of their routine cancer care
Exclusion
- N/A
Key Trial Info
Start Date :
January 26 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
10600 Patients enrolled
Trial Details
Trial ID
NCT06081517
Start Date
January 26 2024
End Date
December 1 2028
Last Update
June 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States, 46202